Kintara Therapeutics corrected the record date for issuing Contingent Value Rights (CVRs) to stockholders, now set for immediately before a planned reverse stock split prior to a merger with TuHURA Biosciences, with 53,897,125 shares of common stock to be issued based on certain milestones.